Introduction joint Rash may be considered as a


Chronic obstructive pulmonary disease (COPD) is a chronic respiratory
disease featuring a lack of airflow. The subtypes of COPD include chronic
bronchitis, emphysema and chronic obstructive asthma. This report will be focusing on chronic bronchitis.

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!

order now






























Common signs and symptoms of chronic bronchitis
include chronic productive cough, excessive sputum expectoration, dyspnea, wheezing,
chest tightness, . For severe chronic
bronchitis, cyanosis and weight loss may be experienced.
















Patients have to be diagnosed with
COPD first before













Discussion of new drug’s place in therapy and
recent trials

The drug in discussion for our group is
named olodaterol. It is already in the market in Singapore to manage COPD. The
brand name for olodaterol is STRIVERDI® RESPIMAT®. Striverdi Respimat is a soft
mist inhaler that delivers olodaterol as an inhalation solution. The class of
this medication is long-acting beta2-adrenergic agonist (LABA). The indication
of Striverdi Respimat is for long term, one-time daily maintenance of COPD
including chronic bronchitis and emphysema. During inhalation, bronchodilation
by relaxation of airway smooth muscle cells is achieved by binding to human
beta 2-adrenoceptor. These receptors are predominantly expressed on airway
smooth muscle and are bound to the olodaterol which has high affinity and selectivity
for these receptors. Unlike common LABA like Salmeterol, Striverdi Respimat has
a fast onset of action and long duration of action of at least 24 hours.

Side effects: Nasopharyngitis which is
a cold, dizziness,

And rare side effects like
hypertension and arthralgia which is pain in the joint

Rash may be considered as a
hypersensitivity reaction

And lastly side effects related to
beta-2-adrenergic agonist class such as tachycardia, tremor, fatigue

Phase III trials:

One of the trials à 24 weeks comparizson

Drug-drug interaction


















Chronic bronchitis is an incurable
disease. Patients can only manage the symptoms of chronic bronchitis. The best
outcome for the disease treatment is by undergoing both pharmacological and non-pharmacological
therapy, especially when a diagnosis has been made. Many new drugs are currently under development. For example, companies like